Market Overview

UPDATE: Morgan Stanley Upgrades Forest Laboratories Ahead of Further Financial Upside


In a report published Tuesday, Morgan Stanley analyst David Risinger upgraded the rating on Forest Laboratories (NYSE: FRX) from Equal-Weight to Overweight, and named an $86.00 price target.

In the report, Morgan Stanley noted, “Our Base Case is an earnings and multiple call: cons under-estimates durability of growth. We raised F15E (Mar) EPS 25% from $3.13 to $3.90 (5% above cons) and F16E EPS 23% from $3.86 to $4.73 (9% above cons). Cons is not fully updated for the Aptalis close Feb 3rd, but we believe investors under-appreciate Namenda earnings durability in the wake of the hard conversion to longer patent life XR announced late-Friday Feb 14th. We est. Forest F16-F21 5-yr EPS CAGR of 8%, and we believe cons under-estimates durability of growth and P/E will rise.”

Forest Laboratories closed on Friday at $71.39.

Latest Ratings for FRX

May 2014MaintainsNeutral
Apr 2014MaintainsHold
Apr 2014DowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morgan Stanley Sees LifePoint Hospitals as Riding Medicaid Expansion in 2014

Benzinga's Top #PreMarket Gainers